- By insider

Chairman & CEO of Jazz Pharmaceuticals Plc (30-Year Financial, Insider Trades) Bruce C Cozadd (insider trades) sold 9,600 shares of JAZZ on 03/01/2021 at an average price of $170 a share. The total sale was $1.6 million.

• Warning! GuruFocus has detected 4 Warning Sign with JAZZ. Click here to check it out.

• JAZZ 15-Year Financial Data

• The intrinsic value of JAZZ

• Peter Lynch Chart of JAZZ

Jazz Pharmaceuticals PLC is a biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Jazz Pharmaceuticals PLC has a market cap of $9.18 billion; its shares were traded at around $162.910000 with a P/E ratio of 38.71 and P/S ratio of 3.89. Jazz Pharmaceuticals PLC had annual average EBITDA growth of 22.70% over the past ten years. GuruFocus rated Jazz Pharmaceuticals PLC the business predictability rank of 2.5-star. GuruFocus has detected 1 severe warning sign with Jazz Pharmaceuticals PLC. .

CEO Recent Trades:

• Chairman & CEO Bruce C Cozadd sold 9,600 shares of JAZZ stock on 03/01/2021 at the average price of $170. The price of the stock has decreased by 4.17% since.

• Chairman & CEO Bruce C Cozadd sold 1,500 shares of JAZZ stock on 02/03/2021 at the average price of $156.79. The price of the stock has increased by 3.9% since.

For the complete insider trading history of JAZZ, click here

.This article first appeared on GuruFocus.